INTRODUCTION
To evaluate enhancements to the UKB genetic variation resource through WES, we compared the 122 number of coding variants observed in 49,797 individuals in whom both WES and imputed sequence were 123 available; this is a subset of the 49,960 individuals with WES. To capture as many variants in the overlap 124 of WES and imputed sequence as possible, only minimal filtering was applied (WES sites were filtered 125 using genotype likelihoods, with no filtering for imputed data), thus variant counts are greater than in Table   126 2 and Sup. 
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We also noted that amongst all the 707,124 imputed coding variants, 22.6% of them were not 153 observed in the exome sequence data; a large portion of these will similarly suffer from poor imputation 154 accuracy as observed in WES and imputed sequence concordance ( Figure 2 ). As expected, common 155 variants across functional prediction classes were more likely to be captured by both WES and imputed 156 sequence, whereas rare variants were more likely unique to WES (Sup. Table 2 ). As an expected result of 157 purifying selection, we observed that lower frequency variants were predicted to be more deleterious as 158 measured by CADD 15 score distributions in both datasets ( Figure 1b ). Interestingly, among rare variants, 159 those identified by WES were typically classified as more deleterious (Figure 1b ) -likely because rare 160 variants that can be imputed may often be common in other populations even when rare in UKB.
162
Concordance of WES, Directly Genotyped Array, and Imputed Sequence
163
We measured concordance between WES and array genotypes in individuals with both datasets 
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Extrapolating, we can estimate the number of genes where multiple loss of function carriers will 218 be observed once our experiment is complete and all ~500,000 participants are sequenced. Cautiously, we 219 currently predict that >17,000, >15,000, and >12,000 genes will have ≥10, ≥50, and ≥100 heterozygous 220 LOF carriers in the full dataset (see Sup. Methods, Sup. Methods Fig. 1 
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Methods), we obtain 17,640 genes with LOFs in UKB and 17,856 in gnomAD (Sup. Methods Table 2 ).
229

Survey of Medically Actionable Pathogenic Variants
230
To date, more than 5,000 genetic disorders have been described for which the molecular causes and As an example, we evaluated the risk of cancer in individuals carrying pathogenic variants in BRCA1 or BRCA2 (Figure 3b ) to compare across five previously implicated BRCA1/2 associated cancers 23 287 as well as to explore whether risk was conferred for other cancers. While BRCA1 and BRCA2 have 288 differences in mechanism and risk among cancer subtypes, due to low sample sizes, we analyzed summed 289 counts in 114 males and 110 females with BRCA1/2 reported pathogenic and likely pathogenic variants.
290
We found the prevalence of cancers to be elevated in carriers of pathogenic variants in BRCA1/2 for the 5 291 cancers (breast in females, ovarian, prostate, melanoma, and pancreatic) previously associated with BRCA1 292 or BRCA2 (cancer status was derived from self-report, HES, and cancer prevalence for any of the 5 cancers 293 was 21.0% in carriers vs 6.6% in non-carriers, OR = 3.75 (95%CI 2.71,5.18), p-value = 2x10 -12 , (3337 294 cases, 46599 controls), and there was no significant difference between carriers and non-carriers when all 295 other cancers, excluding these 5, were combined; 15.7% in carriers vs 17.7% in non-carriers, OR = 0.86 296 (95%CI 0.58,1.29), p-value = 0.55, (8300 cases, 38424 controls). The most prevalent cancers in this group 297 were C443 and C449 unspecified malignant neoplasms of skin, and D069 carcinoma in situ of cervix.
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Increased risk was observed in these BRCA1/2 variant carriers for each of the five previously associated 
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one of which could be imputed (rs753138805, encoding a frameshift predicted to result in early protein 389 truncation). In analysis of all 500k UKB participants, rs753138805 was significantly associated with 390 decreased BMD (-0.4 SD, P=8.1x10 -19 ) and showed a trend for increased risk of osteoporosis (N=3,495 391 cases, OR=1.9, P=0.10, Sup. Table 16 ). These findings are corroborated by a query of the HUNT study 37 ,
392
where rs753138805 was associated with decreased BMD (-0.5 SD, P=2.1x10 -18 ) and increased risk of any 393 fracture (N=24,155 cases, P=1.6x10 -5 , OR=1.4) (Sup. greater odds of any of the 5 cancers previously associated with BRCA1/2; prevalence for any of the 5 cancers 470 was 21.0% in carriers vs 6.6% in non-carriers. We further explored whether these variants conferred risk to 471 any other cancers and did not observe any such associations. This resource will be valuable for assessment 472 of variant pathogenicity, particularly for variants of unknown significance and novel variants, and in 473 exploring the full spectrum of disease risk and phenotypic expression. One limitation of the resource for 474 such purposes is limited ancestral diversity. This and other similar studies also highlight the value and 475 potential to apply large scale sequencing at the population scale to identify a meaningful proportion of 476 individuals who are at high risk of diseases where effective interventions are available that can significantly reduce the morbidity and mortality of genetically susceptible individuals; such precision medicine approaches could substantially reduce the burden of many diseases.
we also identified a handful of significant novel LOF associations highlighting novel biology and genetics 482 of large effect on disease traits of interest; this included PIEZO1 for varicose veins, MEPE for bone density,
483
and COL6A1 for corneal thickness, amongst others. We identified a novel burden association in PIEZO1, 484 a mechanosensing ion channel present in endothelial cells in vascular walls, that confers a nearly five-fold 485 increased odds of varicose veins in heterozygous LOF carriers. We also identified a novel LOF burden 486 association in MEPE with decreased BMD and an approximately 2-fold increased odds of osteoporosis and more significant than any single LOF variant included in the burden test, highlighting the value of WES 490 and the ability to detect novel associations driven by rare coding variation. While these regions had 491 previously been identified in genome-wide association studies of >10x the sample size, a key strength of 492 the current approach is compelling identification of likely causal genes and the direction of effect: two key 493 pieces of information required for translation towards novel therapeutics. This survey of rare LOF 494 associations was limited by sample size for most binary traits but was well powered for many quantitative 495 traits. While surveys of LOF variation in the entire UKB study using array and imputed sequence have greatly expand the total amount of rare coding variation ascertained, including the number of heterozygous LOF instances that can now be observed in nearly all genes and the number of genes for which naturally 503 occurring homozygous knockouts can be observed. Coupled with rich laboratory, biomarker, health record, 504 imaging, and other health related data continually added to the UKB resource, exome sequencing will 505 enhance the power for discovery and will continue to yield many important findings and insights. The WES 506 data is available to approved researchers through similar access protocols as existing UK Biobank data (see 507 URLs). 508 509 loci for intraocular pressure. Nat Commun 8, 2108, doi:10.1038/s41467-017-01913-6 (2017).
